NPM1 and acute myeloid leukemia: In this first study, Ziftomenib was particularly effective in patients exhibiting the NPM1‐mutated AML subtype, with 35% of patients treated at the recommended phase 2 dose achieving CR (with MRD negativity in 57% of those patients).104